Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna, Austria.
Hepatol Int. 2023 Oct;17(5):1205-1214. doi: 10.1007/s12072-023-10515-y. Epub 2023 Apr 6.
Prophylactic endoscopic band ligation (EBL) is used to prevent variceal bleeding in patients with liver cirrhosis. The association of thrombocytopenia, high INR (international normalized ratio) and liver dysfunction with the risk of procedure-related bleeding (PRB) remains debated and recommendations are controversial.
We analyzed real-life data of cirrhotic patients undergoing elective EBL at two large Viennese centers between Q1/2000-Q1/2018. PRB was defined as bleeding occurring within 30 days after EBL.
We included 617 patients undergoing a total of 1178 prophylactic EBL procedures (median 2 per patient). Sixteen (2.6%) of 617 patients experienced PRB after a median of 12.5 (IQR 17.3) days with no difference in characteristics and laboratory values between the two groups. The proportion of patients with platelets (PLT) < 50 G/L or INR ≥ 1.5 was similar in patients with vs. without PRB. A higher MELD showed a non-significant association with EBL-related bleeding risk (odds ratio, OR 1.07; 95% confidence interval 95% CI 1.00-1.16, p = 0.058). While serum bilirubin was a significant predictor for PRB (OR: 1.10; 95% CI 1.03-1.18), the presence of large varices (OR 0.85 vs. small varices; 95% CI 0.20-3.84), INR (OR 0.50; 95% CI 0.10-3.14), PLT (OR 1.00; 95% CI 1.00-1.01) and the use of non-selective betablockers (OR 1.20; CI 95% 0.38-3.76) were not associated with PRB.
EBL is safe and procedure-related bleedings are rare (2.6%) including in patients with thrombocytopenia < 50 G/L or high INR ≥ 1.5. Only high MELD, and especially high bilirubin seem to be linked to an increased risk of EBL-related bleeding.
预防性内镜套扎(EBL)用于预防肝硬化患者的静脉曲张出血。血小板减少症、高国际标准化比值(INR)和肝功能障碍与与内镜套扎相关出血(PRB)风险的关联仍存在争议,相关建议也存在争议。
我们分析了 2000 年第一季度至 2018 年第一季度期间,在维也纳的两个大型中心接受择期 EBL 的肝硬化患者的真实数据。将 EBL 后 30 天内发生的出血定义为 PRB。
我们纳入了 617 名接受了总共 1178 次预防性 EBL 治疗的患者(每名患者中位数 2 次)。617 名患者中有 16 名(2.6%)在中位数为 12.5(IQR 17.3)天之后出现 PRB,两组之间的特征和实验室值无差异。血小板(PLT)<50 G/L 或 INR≥1.5 的患者比例在有或没有 PRB 的患者中相似。较高的 MELD 与 EBL 相关出血风险无显著相关性(比值比,OR 1.07;95%置信区间 95%CI 1.00-1.16,p=0.058)。尽管血清胆红素是 PRB 的显著预测因素(OR:1.10;95%CI 1.03-1.18),但大静脉曲张(OR 0.85 与小静脉曲张;95%CI 0.20-3.84)、INR(OR 0.50;95%CI 0.10-3.14)、PLT(OR 1.00;95%CI 1.00-1.01)和非选择性β受体阻滞剂的使用(OR 1.20;95%CI 0.38-3.76)与 PRB 无关。
EBL 是安全的,与内镜套扎相关的出血很少见(2.6%),包括血小板减少症<50 G/L 或 INR≥1.5 的患者。只有高 MELD,特别是高胆红素似乎与内镜套扎相关出血的风险增加有关。